Your SlideShare is downloading. ×
Clinical research   ppt,
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Clinical research ppt,


Published on

Published in: Business

  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. BASICS OFBASICS OF CLINICAL RESEARCHCLINICAL RESEARCH P. K. MitraP. K. Mitra Manager – Marketing ServicesManager – Marketing Services Eurodrug Laboratories - IndiaEurodrug Laboratories - India
  • 3. Drug Discovery & Development Process involvesDrug Discovery & Development Process involves 1.1. Target SelectionTarget Selection 2.2. Target ValidationTarget Validation 3.3. Drug / Lead SelectionDrug / Lead Selection 4.4. Lead OptimizationLead Optimization 5.5. Pre-Clinical testingPre-Clinical testing 6.6. Clinical TestingClinical Testing
  • 5. • A Systematic Investigation in Human SubjectsA Systematic Investigation in Human Subjects forevaluating the Safety & Efficacy of any Newforevaluating the Safety & Efficacy of any New Drug.Drug. • Clinical Trial is the main stay for bringing out NewClinical Trial is the main stay for bringing out New Drugs to the Market.Drugs to the Market. • Clinical Trials done in 4 Phases ( I, II, III, IV )Clinical Trials done in 4 Phases ( I, II, III, IV ) • It takes Approx. 10-12 Years & USD 800 Mio toIt takes Approx. 10-12 Years & USD 800 Mio to bring one New Drug to the Market.bring one New Drug to the Market. • For Every 10,000 – 30,000 drug moleculesFor Every 10,000 – 30,000 drug molecules screened, only 1 reaches to the Market.screened, only 1 reaches to the Market.
  • 7. • DCGI under CDSCO has the Prime responsibility for Regulating CTs in India. • Declaration of Helsinki by WMA provides Ethical Guidelines & Principles to the Physicians, Other Participants & Human Subjects. • ICMR code includes statement of general & specific principles on research using human subjects in biomedical research.
  • 8. • ICH-GCP Guidelines unified standard for EU, Japan & USA to facilitate the mutual acceptance of Clinical Data by the Regulatory Authorities in these Jurisdiction. • Indian GCP Guidelines are in line with WHO, ICH, USFDA, and European GCP Guidelines as well as ICMR Code. • Drugs & Cosmetics Act 1940, & Schedule Y tells the requirement and guidelines on Clinical Trials for Import & Manufacture of New Drug in India
  • 10. Stakeholders of the Clinical Trials are: • SPONSORS • Contract Research Organization ( CRO ) • INVESTIGATORS • ETHICS COMMITTEE • REGULATORY AUTHORITY • STUDY SUBJECT ( PATIENTS )
  • 11. • Sponsor takes the responsibility for the Initiation, Management, and/or financing the Clinical Trial. • CRO is the Organization Contracted by the Sponsor to Perform One or More of Sponsor’s Trial related Duties and Functions. • Investigator is responsible for the Conduct of a Clinical Trial at a Site. • Ethics Committee ensures prtection of Rights, Safety, and Wellbeing of the Subjects involved and to provide Public Assurance of the Protection • Study Subjects ( Patients ) are Individual who Participate in the Study ( CT ) Voluntarily.
  • 13. • Essential Clinical Trial Documents individually and collectively evaluates the conduct of a Trial & Preserves the integrity of the Data. • These Documents demonstrate the Compliance of the Investigators and Sponsors/ CRO with GCP & all applicable Regulatory Requirements. • They include, Base Records, Laboratory Data, CRFs, Randomization Key, Other Investigational Records, EC-NOC, DCGI-NOC, ICF, CRO- Sponsor Agreement.
  • 15. • Clinical Trials are different than routine Medical Care. • India became a member of WTO in 1995 and agreed to adhere to Product & Process Patent regime from 2005. • India provides excellent environment for CT: in terms of Less Cost, Speed, Quality Parameters of Global Clinical Trials leading to Significant Growth in Clinical Trial outsourcing to India.
  • 17. • Study Team at Trial Site include Investigator, Co- Investigator, Study Coordinator, Nurse, Pharmacist. • Unblinded Personnel (Coordinator/Nurse/Pharmacist) are required in blinded Trials for dispensing the Trial Medications to the Study Subjects • Clear delegation of duties to the study team members is essential for the smooth execution of a clinical Trial.
  • 18. Individual Member of the Study Team can be delegated specific Trial Duties such as: • Administration of ICF • Recruitment of Subjects • Correspondence with EC / CRO / Sponsors • Stoarge, Dispensing & Accountability of Drugs • Completion of Source Documents • Completion of CRF • Medical Management of the Trial Subject • Reporting of SAE ( Adverse Events ) • Escalations, Resolutions, Management of Deviations • Logistics Management • Resolution of Data Enquiries • Patient’s Visit Scheduling, Protocol Compliance & Follow Up • Maintenance of Site Master File. • Compliance with GCP & Regulatory Guidelines • Tracking of Payments / Study Grants
  • 20. • EC must have written SOP on its Compositions, Functions & Operations. • The Composition of EC must have 7 Members • The Chairman of EC should be from outside of the Institution ( Non Affiliated member ).
  • 21. • The Quorum of EC should have min. 5 Members ( Medical Scientist / Pharmacologist, Clinician, Theologian / Social Scientist / Ethicist, Legal Expert, Lay person. ) • No CT should be initiated at any Site without obtaining written NOC from the respective EC. • If any Investigator or Study team Member is a part of EC, they should abstain from voting on their research proposal.
  • 22. • Version Number of all the essential trial documents approved by EC should be clearly mentioned on the approved letter. • All serious & unexpected ADR should be reported to EC within 7 working days of their occurrence. • EC should maintain its records for at least 5 years after the completion / termination of the study
  • 24. • Source data/documents refer to the documents where the informations on patient’s medical condition and treatment is recorded for the first time. • SD should contain accurate, authentic, and complete information on patient’s medical condition, laboratory results, treatment administered, adverse events & corrective medications.
  • 25. • SD should have proper control & access. • Should reveal what was done & when • All the information regarding patient’s Physical Laboratory, Medical Tests should be kept in one file with valid signatures & dates of the concerned personnel. • SD should be properly archived for preservation • Electronic data for SD should be ensured for Security, Validation & Back up control.
  • 27. • Space for storing Trial documents & materials • Communication facility • Local laboratory facility • USG / Biopsy / CT-Scan / MRI Scan facility • Wards / ICU / Operation Theatre facility • Archival Facility • SOP • Lockable Trial Rooms / Storage Cabinets • Lockable Cabinets, Fridge • National or Internationally accredited Laboratories • Well defined Quality control standards
  • 29. • Well defined rules & regulations of the site. • SOP for Trials & Subject recruitment • Recruit Study Coordinator, Research Staff • Ensure Storage & Archival facility • Tripartite / Bipartite Agreement
  • 31. • Ensurance of Non Disclosure of Agreement by the Site / Invetsigator as per Sponsor / CRO. • Maintain Confidentiality of Information given by Sponsor / CRO to the Site / Investigator. • Sponsor / CRO evaluates the Site, reviews the Qualification of Study Team Members. • Evaluates Composition,Operations, EC Operating System, Source Documentation Practices & Infrastructures of the Site.
  • 32. PROCESS OF SITE EVALUATION Sponsor / CRO approaches the investigator site for discussing a Clinical Trial Proposal Investigator’s concensus / approval is obtained based on Study Protocol discussion NDA is executed between Investigator & Sponsor/CRO Investigator Provides his details on Study Feasibility Questionnaire If Investigator’s response is satisfactory & meets the expectations of Sponsor / CRO, Site Evaluation Visit ensured. Site is either selected / rejected based on the report of Site Evaluation done by Sponsor / CRO Representative
  • 34. Sponsor/CRO forwards the following documents to the Clinical Investigator for Review & Completion: 1. Study Protocol 2. Patient Information Sheet & PIC (English & Vernacular) 3. Investigator Brochure 4. Case Record Form 5. Insurance / Indemnity Certificate 6. Patient Diaries / Questionnaire 7. Format of Undertaking by Investigator 8. Draft of CTA between Investigator & Sponsor / CRO 9. Regulatory Clearance ( DCGI ) NOC 10. No. of copies of above documents for EC application
  • 35. • Site is selected for CT after successful Evaluation of the Site by the Sponsor / CRO. • Careful CTA drafting & Suggestions can avoid issues like, Payment Delays, Frequent Amendments, Retain Dedicated Study personnel. • Investigators Training Meeting is conducted to provide a uniform understanding of Protocol & process to all the Participants.
  • 37. Site Initiation Visit by Sponsor verifies that Investigator & his Team are Trained on the Study Requirements. 1. Essential Trial Documents 2. Roles & Responsibilities of each Team Member 3. Facilities, Role of Sponsor, Study Time lines 4. ICF & CRF 5. SAE / ADR Reporting 6. EC – NOC Application Requirements 7. Source Documents 8. Study Drug Storage / Accounatbility 9. Randomization Procedures 10. Data Management 11. Audits / Inspections & Archival
  • 38. • Performed to evaluate the preparedness of the Investigator Site for Subject Enrollment. • It is done after EC-NOC obtained & fulfillment of all the Protocol Requirements. • Review the preparedness of the Study Team on all the Requirements for the Study • Revisit the Critical Study Supplies for the Study before Enrollment of the Subjects. • Opportunity to check the Critical Aspects of The Trial after initial Training & before implementation Phase.
  • 40. • ICF is a procedure to take the consent of the participant after being completely briefed about the Trial & Outcome, etc. • Sponsor has the responsibility to detail all the risks, regulatory needs & procedures of the Trial in the ICF in vernacular of the subject. • ICF must be obtained before non-routine screening procedures are performed and/or before any change in the subject’s current medical therapy. • The subject & the Investigator obtaining the ICF must sign the ICF with date at the appropriate places.
  • 41. • One copy of the signed ICF should be given to the subject and ICF should be obtained by the Investigator. • In case the Subject is illiterate, one impartial person should be present during ICF discussion & signing. • Any amendment done in the obtained ICF should be subjected to EC approval & the subject should be re- consented. • Only EC approved ICF should be used for all enrollment. • Data required in the Protocol should be carefully recorded in the source documents & later transcribed in the CRF.
  • 43. • Source Documents should tell the complete story of the trial & aid in reconstruction of total information. • CRFs as SD refer to Quality of Life Questionnaire, Evaluation Scales, Patient demographics and it should be mentioned in the protocol. • Documentation of all Transactions of the Study Drug would lead to 100% drug accountability. • Incomplete & Inappropriate SD can lead to Audit Issues & well maintained SD helps in reconstruction of the Study at any point of time. • All SD are required to be archived for a specific period of 10-15 years after completion of the Study for future Audit.
  • 44. A Good Source Document should be able to address the following. : 1. ICF Process 2. Pre-existing Conditions & Relevant History 3. Laboratory Reports & Results 4. Efficacy Evaluations 5. Adverse Events & Corrective Medications 6. Drug Accountability 7. Progress Notes 8. Ongoing Patient’s Status
  • 45. THANK YOU